A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects With Psoriasis Vulgaris

NCT01268527 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis Vulgaris

Interventions

DRUG: 0.03% E6201
DRUG: 0.1% E6201
DRUG: 0.2% E6201
DRUG: 0.005% E6201
DRUG: 0.01% E6201
DRUG: 0.05% E6201
OTHER: Placebo - 0.03% gel vehicle
OTHER: Placebo - 0.1% gel vehicle
OTHER: Placebo - 0.2% gel vehicle
OTHER: Placebo - 0.05% gel vehicle
OTHER: Placebo - 0.01% gel vehicle
OTHER: Placebo - 0.05% gel vehicle
DRUG: Calcipotriene

Sponsor

Eisai Limited